D-5600 Daporinad, Free Base, >99%

Synonyms : [APO866] [FK866] [K22.175] [WK175]

  • Size
  • US $
  • £
  • ¥
  • 5 mg
  • 59
  • 54
  • 46
  • 9,200
  • Add to Cart Qty:
  • In stock
  • 10 mg
  • 98
  • 90
  • 77
  • 15,300
  • Add to Cart Qty:
  • In stock
  • 25 mg
  • 212
  • 195
  • 166
  • 33,000
  • Add to Cart Qty:
  • In stock
  • 50 mg
  • 365
  • 335
  • 287
  • 56,800
  • Add to Cart Qty:
  • In stock
  • 100 mg
  • 597
  • 549
  • 469
  • 92,900
  • Add to Cart Qty:
  • In stock
  • 200 mg
  • 985
  • 906
  • 775
  • 153,300
  • Add to Cart Qty:
  • In stock

Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.

To receive a Formal Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities Free Shipping and Handling to the U.S. and 32 Other Countries
  • M.W. 391.51
  • C24H29N3O2
  • [658084-64-1]

Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO.

Select Lot Number to view Certificate of Analysis

View the SDS for this product

  • Daporinad, also known as FK-866, is a highly specific, noncompetitive inhibitor of nicotinamide phosphoribosyltransferase (NAPRT) with Ki values of 0.4 nM for the enzyme/substrate complex and 0.3 nM for the free enzyme, respectively. NAPRT is a key enzyme in the regulation of NAD+ biosynthesis from the natural precursor nicotinamide. Daporinad initiated apoptosis by gradual depletion of the intracellular coenzyme NAD+. Hasmann M.1. and Schemainda I. "FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis." Cancer Res. 63: 7436-7442 (2003).
  • Daporinad was capable of reducing the secondary inflammatory injury and partly reducing permanent damage after spinal cord injury. NAPRT protein levels were increased upon spinal cord injury in the perilesional area, which was corrected by daporinad. Esposito E., et al. "The NAMPT inhibitor FK866 reverts the damage in spinal cord injury." J. Neuroinflammation 9: 66 (2012).
  • Reciprocal potentiation of the antitumor activities of daporinad and etoposide or cisplatin was observed in neuroblastoma cells. Travelli C., et al. "Reciprocal potentiation of the antitumoral activities of FK866, an inhibitor of nicotinamide phosphoribosyltransferase, and etoposide or cisplatin in neuroblastoma cells." J. Pharmacol. Exp. Ther. 338: 829-840 (2011).
  • This daporinad product is the free base, whose CAS number is given above. As of May 18, 2016, no CAS number had been reported for the hydrochloride salt.
  • Another CAS number previously assigned to Daporinad, namely 1198425-96-5, has been deleted by CAS and is no longer in use.
  • Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.
  • This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
  • Not available in some countries; not available to some institutions; not available for some uses.